Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761884 | 0.95 | KDM4E (0.47) | HRH3KDM4EHTR7MAOB | |
| SCHEMBL12449634 | 0.87 | KDM4E (0.50) | HRH3KDM4EHTR7 | |
| SCHEMBL13077 | 0.87 | KDM4E (0.50) | HRH3KDM4EHTR7 | |
| SCHEMBL13995508 | 0.87 | KDM4E (0.50) | HRH3KDM4EHTR7 | |
| SCHEMBL7771642 | 0.86 | KDM4E (0.47) | HRH3KDM4EHTR7MAOB | |
| SCHEMBL9374424 | 0.85 | HRH3 (0.53) | HRH3KDM4EHTR7MAOB | |
| SCHEMBL17574727 | 0.83 | SIGMAR1 (0.47) | HRH3KDM4E | |
| SCHEMBL17574703 | 0.83 | SIGMAR1 (0.47) | HRH3KDM4E | |
| SCHEMBL9322433 | 0.82 | HRH3 (0.41) | HRH3KDM4EHTR7MAOB | |
| SCHEMBL12513823 | 0.81 | BCHE (0.55) | HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HRH3 3363/4885KDM4E 1617/4885HTR7 3702/4885 |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | HAVCR2, AR, AKR7A2 | HRH3 859/4885KDM4E 2363/4885HTR7 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.